Red Light Holland Acquires Filament Health in Strategic Psychedelic Drug Development Merger

Red Light Holland Corp. (搜索)搜索该词条 and Filament Health Corp.查看公司主页 announced March 10, 2026, that they have entered into a definitive arrangement agreement for Red Light to acquire Filament's business through a statutory plan of arrangement. The all-share transaction combines two complementary platforms in natural psychedelic drug development, with existing Red Light shareholders expected to retain approximately 70% ownership following closing.

Strategic Assets Integration

The merger brings together Filament's extensive intellectual property portfolio of 76 issued patents across 15 patent families covering natural psilocybin查看药品详情 extraction, purification, standardization, stabilization, and alternative delivery formulations. Filament operates a GMP-compliant pharmaceutical manufacturing facility in Vancouver and holds a Health Canada查看公司主页 Level 8 Controlled Substances Dealer's Licence, providing critical regulatory infrastructure for controlled substance development.

Filament's lead botanical psilocybin查看药品详情 drug candidate, PEX010查看药品详情, currently supplies more than 70 clinical research sites globally and supports clinical trial supply as well as regulated compassionate use programs in several jurisdictions. The company has established itself as a leading supplier of pharmaceutical-grade natural psilocybin supporting over 70 academic and philanthropic research studies worldwide.

Red Light contributes operational capabilities across mushroom and truffle cultivation, consumer product development, distribution infrastructure, and brand building. The company has generated real-world insights through responsible microdosing initiatives and published protocols designed to better understand consumer behavior and usage patterns.

Clinical Development Pipeline

The combined organization intends to evaluate opportunities to expand its clinical development pipeline, including the potential advancement of Phase 2 clinical trials investigating psilocybin查看药品详情-assisted therapies for substance use disorders (搜索)搜索该疾病 and related mental health conditions (搜索)搜索该疾病, subject to regulatory approvals and available funding.

"This marks a strategic milestone for Red Light as we accelerate our focus on regulated psychedelic medicine and clinical drug development," said Todd Shapiro, Chief Executive Officer and Director of Red Light. "Filament's established and unique intellectual property, GMP manufacturing, comprehensive Health Canada查看公司主页 licensing, an FDA-authorized clinical program, and broad global distribution of their botanical psilocybin查看药品详情 drug candidate, PEX010查看药品详情."

Benjamin Lightburn, Chief Executive Officer and Co-Founder of Filament, stated: "Our Health Canada and FDA-authorized clinical programs, GMP facility, and Health Canada查看公司主页 Dealer's Licence provide a strong scientific and regulatory foundation. Red Light's capital resources, operational infrastructure, and commercial experience will help accelerate clinical development and expand the reach of our natural psychedelic drug candidates."

Commercial Strategy

The transaction positions the combined company to advance commercialization of patented microdosing psilocybin查看药品详情 drug candidates, targeting jurisdictions with emerging regulatory pathways for clinical supply and distribution to authorized clinical research studies, compassionate use programs and other authorized uses.

Following completion of the arrangement, the combined company is expected to consolidate intellectual property, research and development, manufacturing, clinical trial supply, data insights, and international distribution capabilities under a single platform. This integration is anticipated to expand opportunities across API licensing, clinical trial supply partnerships, compassionate use access programs, and international pharmaceutical distribution initiatives.

Transaction Terms

Under the arrangement agreement, each outstanding common share of Filament will be exchanged for consideration shares of Red Light, based on an exchange ratio to be determined at a deemed price per consideration share equal to the greater of $0.02 (the floor price), the ten-day VWAP of Red Light shares ending five business days prior to the effective date, or the ten-day VWAP commencing the first full business day following the public announcement.

Assuming the floor price is utilized, the exchange ratio is anticipated to be 0.0756. In aggregate, up to 182,447,452 consideration shares are issuable under the arrangement, which includes shares issuable in settlement of certain of Filament's existing debt obligations and transaction bonuses.

The consideration shares will be subject to resale restrictions, with 50% released six months after closing, 25% at nine months, and the remaining 25% at twelve months. Certain Filament shareholders have agreed to deposit approximately 7.5% of the consideration shares in escrow for 12 months following closing to secure indemnification obligations.

Regulatory Approvals

The transaction is subject to approval of Filament shareholders at a special meeting expected to be convened by Filament, receipt of required regulatory and court approvals, and other customary conditions of closing. Approval of Red Light shareholders is not required. The transaction is currently anticipated to be completed in Q2 2026, subject to receipt of all regulatory, court, shareholder and other approvals.

The board of directors of Filament unanimously recommends that Filament shareholders vote in favour of the resolution to approve the transaction and has determined that the consideration offered is fair from a financial point of view. Evans and Evans, Inc. (搜索)搜索该词条 has provided a fairness opinion stating that the consideration to be received by holders of Filament shares is fair from a financial point of view.